Clinical trials: Endometrial Adenocarcinoma
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Prostate Cancer, Hepatocellular Carcinoma
68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
This study aims to evaluate a novel dual-targeted PET imaging tracer, 68Ga-FAPI-PSMA, for the detection and evaluation of solid tumors.
- Conditions
- Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors
- Trial name
- NCT07639801
- Testing
- 68Ga-FAPI-PSMA, 68Ga-PSMA-617, 68Ga-FAPI-04
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Endometrial Cancer, Endometrial Adenocarcinoma
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer.
- Trial name
- NCT05824481
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-)
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced…
- Conditions
- Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor
- Trial name
- NCT04165772
- Testing
- TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
- Where
- 10 sites in United States
- Volunteers
- 212 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT03660826
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 761 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd
Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
This pilot, phase II trial studies the side effects and how well paclitaxel given into the vein and carboplatin given directly into the abdominal cavity (intraperitoneally) followed by radiation therapy work in treating patients…
- Conditions
- Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer
- Trial name
- NCT02112552
- Testing
- Paclitaxel, Carboplatin, 3-Dimensional Conformal Radiation Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Albert Einstein College of Medicine
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Endometrial Serous Adenocarcinoma
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy
This early phase I trial investigates the response to the anti-cancer drug, triapine, in uterine cancers by using markers from tissue samples at the time of removal of the uterus, ovaries, and fallopian tubes (hysterectomy and…
- Trial name
- NCT04494113
- Testing
- Biopsy Procedure, Biospecimen Collection, Resection
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, ERBB2 Gene Amplification
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Endometrial Adenocarcinoma, ERBB2 Gene Amplification, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00006089
- Testing
- Laboratory Biomarker Analysis, Trastuzumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Endometrial Cancer
Papillary Serous Carcinoma of the Endometrium
Primary Objectives: To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival.
- Trial name
- NCT00515073
- Testing
- Paclitaxel, Pelvic Radiation, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
- Conditions
- Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04681248
- Testing
- DKN-01
- Where
- 5 sites in United States
- Sponsor
- Leap Therapeutics, Inc.
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals